Acquired by PMC International in December of 2017, PMC Isochem is a world leader in custom pharmaceutical manufacturing. We are a fully integrated business comprised of research, product/process development, regulatory approvals, pilot scale and full plant-scale production of drug intermediates and active pharma ingredients (APIs) for major pharmaceutical companies worldwide to serve the needs of Oncology, Cardiovascular, Infectious, Gastro-Intestinal, Neurology and rare diseases. These facilities, with a combined footprint of over 40 acres, are located at three sites -- Gennevilliers, Pithiviers, and Vert-Le-Petit -- within a 60 miles radius of Paris. The facilities are all cGMP US-FDA audited plants for manufacturing pharmaceutical products. As a leading contract drug development and manufacturing organization (CDMO), we are masters of complex processes and can manufacture products to the most stringent pharmaceutical regulatory standards. We serve a broad range of customers in many application fields, from leading global companies to virtual and emerging organizations. PMC Isochem offers services in three pharma-related fields: custom synthesis, high technology manufacturing in multi-step chemical synthesis and direct supply 100 specific compounds and products, including regulated and non-regulated intermediates and active ingredients. Technical strengths include high-pressure chemistry, low-temperature chemistry, hazardous chemistry, and peptide chemistry. We are continually expanding our technology platform and service offerings to meet customer demand. |